Vinay K Rathi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7067821/publications.pdf

Version: 2024-02-01

687363 580821 71 810 13 25 citations h-index g-index papers 71 71 71 974 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Using Machine Learning to Predict Operating Room Case Duration: A Case Study in Otolaryngology. Otolaryngology - Head and Neck Surgery, 2023, 168, 241-247.	1.9	11
2	Variation in the Price of Head and Neck Surgical Oncology Procedures. Otolaryngology - Head and Neck Surgery, 2023, 168, 536-539.	1.9	3
3	Private Payer–Negotiated Prices for Outpatient Otolaryngologic Surgery. Otolaryngology - Head and Neck Surgery, 2022, 167, 262-265.	1.9	10
4	Contemporary Incremental Healthcare Costs for Allergic Rhinitis in the United States. Laryngoscope, 2022, 132, 1510-1514.	2.0	3
5	Private payerâ€negotiated prices for FDAâ€approved biologic treatments for allergic diseases. International Forum of Allergy and Rhinology, 2022, 12, 798-801.	2.8	6
6	Outâ€ofâ€pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. International Forum of Allergy and Rhinology, 2022, 12, 1295-1298.	2.8	6
7	Payer-Negotiated Prices for Telemedicine Services. Journal of General Internal Medicine, 2022, 37, 3495-3497.	2.6	14
8	Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. JAMA Internal Medicine, 2022, 182, 603.	5.1	13
9	Defining the Health Utility Value of Medical Management of Chronic Rhinosinusitis: A Prospective Pilot Study. OTO Open, 2022, 6, .	1.4	1
10	Medical Device User Fee Reauthorization â€" Back to Basics or Looking Ahead?. New England Journal of Medicine, 2022, 387, 196-199.	27.0	2
11	Price Transparency for COVID-19 Testing Among Top US Hospitals. Journal of General Internal Medicine, 2021, 36, 245-247.	2.6	2
12	CARES Act Provider Relief Fund Aid to Otolaryngologists in Small Practices. Otolaryngology - Head and Neck Surgery, 2021, 164, 542-544.	1.9	3
13	Physician Performance in the Medicare Merit-based Incentive Payment System. JAMA - Journal of the American Medical Association, 2021, 325, 308.	7.4	2
14	Medicare Reform of Hospital Payment for Inpatient Facial Plastic Procedures. Facial Plastic Surgery and Aesthetic Medicine, 2021, 23, 2-4.	0.9	2
15	Moving Toward Equitable Telemedicine in Otolaryngology–Head and Neck Surgery—Reply. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 220.	2.2	1
16	Educational utility of an online <scp>videoâ€based</scp> teaching tool for sinus and skull base surgery. Laryngoscope Investigative Otolaryngology, 2021, 6, 195-199.	1.5	4
17	Medicare's New Device-Coverage Pathway — Breakthrough or Breakdown?. New England Journal of Medicine, 2021, 384, e43.	27.0	9
18	Graduate Medical Education in Otolaryngology: Making Dollars and Sense of Reform. Otolaryngology - Head and Neck Surgery, 2021, 165, 762-764.	1.9	3

#	Article	IF	CITATIONS
19	Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. JAMA Internal Medicine, 2021, 181, 1409.	5.1	4
20	Analysis of Price Transparency for Oncologic Surgery Among National Cancer Institute–Designated Cancer Centers in 2020. JAMA Surgery, 2021, 156, 582.	4.3	16
21	Otolaryngologists Trail Other Specialties in Industry Payments From Dermal Filler Companies. Laryngoscope, 2021, , .	2.0	0
22	Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. JAMA - Journal of the American Medical Association, 2021, 326, 184.	7.4	32
23	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2018. Otolaryngology - Head and Neck Surgery, 2021, , 019459982110328.	1.9	1
24	Surprise Billing in Health Care. JAMA - Journal of the American Medical Association, 2021, 326, 569.	7.4	1
25	Analyzing Charge Data Systematically Overestimates Health Care Costs. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 921.	2.2	2
26	Pneumonia, urinary tract infection, bacteremia, and Clostridioides difficile infection following major head and neck free and pedicled flap surgeries. Oral Oncology, 2021, 122, 105541.	1.5	7
27	Compensation Rates for Otolaryngologic Procedures Under the Medicare Physician Fee Schedule in 2018. Laryngoscope, 2021, 131, E1785-E1791.	2.0	3
28	Female Authorship of Opinion Pieces in Leading Otolaryngology Journals between 2013 and 2018. Otolaryngology - Head and Neck Surgery, 2020, 162, 35-37.	1.9	7
29	Implications of Private Equity Acquisition of Otolaryngology Physician Practices. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 97.	2.2	6
30	Regulation of Over-the-Counter Hearing Aids â€" Deafening Silence from the FDA. New England Journal of Medicine, 2020, 383, 1997-2000.	27.0	8
31	Early experience with the FDA's Breakthrough Devices program. Nature Biotechnology, 2020, 38, 933-938.	17.5	20
32	Telemedicine Services Provided to Medicare Beneficiaries by Otolaryngologists Between 2010 and 2018. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 816.	2.2	15
33	Assessment of Gender Differences in Clinical Productivity and Medicare Payments Among Otolaryngologists in 2017. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 822.	2.2	21
34	Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Network Open, 2020, 3, e2014496.	5.9	7
35	Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Internal Medicine, 2020, 180, 1701.	5.1	15
36	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2017. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 639.	2.2	11

3

#	Article	IF	Citations
37	The Case for Value-Based Pricing of Corticosteroid-Eluting Sinus Stents. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 221.	2.2	0
38	National Geographical Variation in Sinus Balloon Dilation. Otolaryngology - Head and Neck Surgery, 2020, 162, 761-766.	1.9	1
39	Trends in Ambulatory Surgery Center Utilization for Otolaryngologic Procedures among Medicare Beneficiaries, 2010â€2017. Otolaryngology - Head and Neck Surgery, 2020, 162, 873-880.	1.9	15
40	CMS Adoption of Prior Authorization Requirementsâ€"Implications for Facial Plastic Surgery. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 397.	2.2	3
41	Preserving and Promoting Competition in the Post–Coronavirus Disease 2019 Healthcare Delivery System. JAMA Health Forum, 2020, 1, e201191.	2.2	2
42	Incomplete Picture of Otolaryngologist Performance in the Merit-Based Incentive Payment Systemâ€"Reply. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 1087.	2.2	0
43	Refining Assumptions About Specialty Compensation Rates. JAMA Surgery, 2020, 155, 1085.	4.3	O
44	Modernizing the FDA's 510(k) Pathway. New England Journal of Medicine, 2019, 381, 1891-1893.	27.0	23
45	Getting More Savings from ACOs — Can the Pace Be Pushed?. New England Journal of Medicine, 2019, 380, 2190-2192.	27.0	12
46	First-Year Report Cards From the Merit-Based Incentive Payment System (MIPS). JAMA - Journal of the American Medical Association, 2019, 321, 1157.	7.4	36
47	The Centers for Medicare & Medicaid Services' Overhaul of Office-Visit Payments—What's the Bottom Line for Otolaryngology?. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 303.	2.2	1
48	Off-label Treatment in Otolaryngologyâ€"A Cautionary Tale. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 399.	2.2	3
49	Use of Corticosteroid-Eluting Sinus Stents Between 2012 and 2017. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 90.	2.2	7
50	Device Safety. Otolaryngologic Clinics of North America, 2019, 52, 103-114.	1.1	2
51	Risk factors for thirtyâ€day readmission following flap reconstruction of oncologic defects of the head and neck. Laryngoscope, 2018, 128, 343-349.	2.0	23
52	Patient Preferences in Subglottic Stenosis Treatment: A Discrete Choice Experiment. Otolaryngology - Head and Neck Surgery, 2018, 158, 520-526.	1.9	17
53	Bundled Payments in Otolaryngology: Early Lessons from Arkansas. Otolaryngology - Head and Neck Surgery, 2018, 159, 945-947.	1.9	10
54	The role of industry influence in sinus balloon dilation: Trends over time. Laryngoscope, 2018, 128, 1540-1545.	2.0	13

#	Article	IF	CITATIONS
55	The Meritâ€based Incentive Payment System (MIPS): A Primer for Otolaryngologists. Otolaryngology - Head and Neck Surgery, 2018, 159, 410-413.	1.9	13
56	Industry Sponsorship of Research in Otolaryngology. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 842.	2.2	8
57	Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005â€2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 683-692.	1.9	2
58	What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment. Otolaryngology - Head and Neck Surgery, 2017, 157, 618-624.	1.9	12
59	US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016. Otolaryngology - Head and Neck Surgery, 2017, 157, 608-617.	1.9	7
60	Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 285-288.	1.9	5
61	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979–2015. Ophthalmology, 2017, 124, 1237-1246.	5.2	2
62	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. BMJ, The, 2016, 354, i5197.	6.0	1
63	The US Food and Drug Administration 515 Program Initiative. JAMA Cardiology, 2016, 1, 117.	6.1	9
64	How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?. Clinical Orthopaedics and Related Research, 2016, 474, 1053-1068.	1.5	26
65	Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013. JAMA Internal Medicine, 2016, 176, 551.	5.1	5
66	Industry Ties in Otolaryngology. Otolaryngology - Head and Neck Surgery, 2015, 152, 993-999.	1.9	70
67	Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration. Otolaryngology - Head and Neck Surgery, 2015, 153, 400-408.	1.9	10
68	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. JAMA - Journal of the American Medical Association, 2015, 314, 604.	7.4	87
69	Sharing of clinical trial data among trialists: a cross sectional survey. BMJ, The, 2012, 345, e7570-e7570.	6.0	112
70	Hospital Prices for Pediatric Tympanostomy Tube Placement and Adenotonsillectomy in 2021. Laryngoscope, 0, , .	2.0	1
71	Payer-negotiated pricing of the hypoglossal nerve stimulator. Journal of Clinical Sleep Medicine, 0, , .	2.6	1